Daiichi Sankyo Company, Limited (DSKYF)

35.03 -1.19 (-3.29%) As of 01:42PM EDT. Market open.

Daiichi Sankyo Company, Limited

3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo 103-8426
Japan
81 3 6225 1111
https://www.daiichisankyo.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Sunao Manabe D.V.M., Ph.D.	Group CEO & Executive Chairperson	1.82M	N/A	1954
Mr. Hiroyuki Okuzawa	President, COO & Representative Director	716.21k	N/A	1962
Kentaro Asakura	Vice President of Corporate Communications Department	N/A	N/A	N/A
Ms. Marielle Cohard-Radice M.D.	Global Head of Development	N/A	N/A	N/A
Akio Sakurai	Corporate Officer, Head of Sales and Marketing Div. & Japan Business Unit	N/A	N/A	N/A
Takashi Matsumoto	Managing Executive Officer, Head of Global HR & CHRO	N/A	N/A	N/A
Mr. Joji Nakayama	Senior Adviser	1M	N/A	1950
Mr. Kiminori Nagao	Corporate Officer & Head of ASCA Business Division	N/A	N/A	N/A
Mr. Joseph Kenneth Keller	Head of Oncology Business Unit	N/A	N/A	1963
Mr. Stuart Mackey J.D.	Global Head of Business Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Corporate Governance

Daiichi Sankyo Company, Limited’s ISS Governance QualityScore as of May 1, 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.